Q-omics provides the consensus-scored TRH profile across patient tissues and cancer cell-line models. TRH expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TRH is differentially expressed in 6, with the highest sampling consensus in BRCA. Additionally, TRH RNA expression shows 11,033 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, BRCA, and TGCT as cancer lineages where TRH shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRH — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRH survival associations across molecular data types. TRH RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRH RNA expression–survival associations across cancer types. High TRH expression shows unfavorable associations in ACC, READ, BLCA and COAD, but favorable associations in LAML and BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TRH RNA expression.
This table summarizes TRH tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for TRH. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRH shows lower tumor expression in UCEC, LUSC, PRAD and HNSC and higher tumor expression in BRCA and THCA. The BRCA box plot shows higher TRH RNA expression in tumor versus normal tissue (log2 FC = +0.554, t-test p = .007).
This table shows molecular features associated with TRH in patient tissues and cancer cell lines. In patient samples, TRH shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TRH RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
